Organic Active Ingredients TRIZ Cases

Carrier bacteria transfer episomal DNA encoding antibacterial agents to target cells through conjugation.

Porous silica particles carry nucleic acid molecules to inhibit connective tissue growth factor expression.

Nogo receptor-1 antagonists reactivate axonal growth and improve neurological recovery in chronic spinal cord injuries where conventional therapies fail.

Afatinib dimaleate Form Alpha resolves processing limitations by providing enhanced thermodynamic stability and bioavailability via distinct crystal structures.

A lactam compound derivative binds D2, 5-HT1A, and 5-HT2A receptors to treat schizophrenia.

Specific (hetero)arylamide structures target the T315I mutation to reduce side effects while maintaining tumor growth inhibition.

Activated carbon decomposes high molecular weight hyaluronic acid to lower molecular weight, eliminating complex pH adjustments and purification steps.

Pyrazine compounds inhibit phosphodiesterase 10 to treat neuropsychiatric disorders by selectively targeting cyclic nucleotide signaling in the basal ganglia.

2'-spiro-nucleosides improve pharmacokinetic profiles and reduce resistance risk by targeting NS5B polymerase.

TAS1R3 protein enables targeted drug delivery to tumor cells, reducing systemic side effects.

Detect EGFR and KRAS mutations via PCR amplification to overcome T790M resistance and improve treatment outcomes in non-small cell lung cancer.

Salsalate nanosuspensions reduce gastrointestinal toxicity by increasing solubility and allowing lower therapeutic doses.

Novel oxadiazole compounds deliver anticonvulsant effects to address insufficient efficacy in refractory focal onset seizure cases.

Merges small molecule penetration with antibody efficacy to overcome blood-brain barrier resistance in HER2-positive disease.

Macitentan at 60 to 90 mg daily resolves the contradiction between disease improvement and side effects like hemoglobin decrease.

Heterocyclic derivatives inhibit HIV protease, reducing side effects while blocking viral replication.

Micronizing tofacitinib below 20 micrometers improves dissolution and content uniformity while maintaining manufacturing simplicity.

Chemically conditioned turmeric compounds inhibit amyloid production and aggregation, restoring long-term potentiation for cognitive decline treatment.

A polyurethane copolymer intravaginal ring delivers multiple drugs with contrasting hydrophilicity through a biostable matrix.

Inhalation delivery of a composite pyrimidine compound reduces right ventricular systolic pressure in pulmonary arterial hypertension.

A pressurized metered dose inhaler solution formulation dissolves multiple active drugs in an HFA propellant and ethanol mixture.

A transdermal gel composition incorporates a volatile siloxane agent to coat solid particulate COX-2 inhibitors.

Oxadiazole compounds act as selective S1P1 receptor agonists to resolve tolerability issues in autoimmune therapy.

Pyrroloquinoline derivatives modify chemical structure parameters to enhance therapeutic efficacy and overcome drug resistance in cancer treatment.

Targeting the LSD1me2-CHD1 interface blocks androgen-dependent transcription while preserving other pathways.

Chromene compounds block the TCR-Nck interface to resolve the contradiction between therapeutic effectiveness and side effects in autoimmune disease treatment.

Combines a somatostatin analogue with a 11beta-hydroxylase inhibitor to treat elevated cortisol levels.

Seeded crystallization yields stable, high-purity phosphonate esters by resolving manufacturing reproducibility challenges in pharmaceutical synthesis.

Proteomic and phosphoproteomic signatures replace FLT3 mutation status to improve prediction precision for midostaurin treatment in acute myeloid leukemia.

A humanized antibody binds VEGFR-2 to block endothelial cell proliferation and tumor vascularization pathways.

Complexing acidic cannabinoids with glucosamine resolves low bioavailability by boosting aqueous solubility and stability against decarboxylation.

An otic formulation transports antiviral agents through the tympanic membrane, enabling targeted upper respiratory treatment without systemic side effects.

Combining steroids with theophylline addresses targeted delivery challenges in managing non-infective nasal symptoms.

Fumigillol derivatives modulate MetAP2 enzyme activity to treat obesity while minimizing side effects through selective tissue distribution.

A pharmaceutical composition combining fluoxetine with vitamin D3 derivatives to promote melanogenesis in skin tissue.

Imidazolyl thiophene sulfonyl carbamates activate AT2 receptors while reducing CYP enzyme inhibition and metabolic hydrolysis.

Canagliflozin down-regulates PD-L1 expression in tumor cells to enhance T cell killing, addressing low response rates from antibody permeability limits.

Scavenger compounds react with malondialdehyde to inhibit platelet activation, extending analysis windows from two hours to seventy-two hours.

Specific miRNAs including miR-3140 suppress tumor growth in colon, pancreatic, and lung cancers.

Targeted RNA interference silences HAO1 transcripts, lowering oxalate production and mitigating renal damage in Primary Hyperoxaluria Type 1.

Dihydroxybenzoate polymers enable controlled drug release through tailored degradation profiles.

Mito-lonidamine concentrates drug action in cancer cell mitochondria, achieving 500-fold higher potency than lonidamine at lower systemic doses.

Humanized antibodies bind LGR5 to block Wnt signaling, reducing cancer stem cell populations and tumor recurrence.

Chemical activation of modified psoralens enables pathogen inactivation in double red blood cell donations while maintaining osmolarity and glucose levels.

siRNA molecules silence PDK1 gene expression to reduce inflammation and systemic toxicity in ocular allergies.

Specific dosing schedules for OKI-179, binimetinib, and encorafenib achieve synergistic tumor regression while managing safety trade-offs.